The Federal Trade Commission issued an Opinion and Final Order in which the Commission upholds the Administrative Law Judge’s decision that the consummated acquisition of Freedom Innovations by Otto Bock HealthCare North America, Inc.—both top sellers of prosthetic knees equipped with microprocessors or MPKs—resulted in anticompetitive harm in the microprocessor prosthetic knee market, likely leading to higher prices and less innovation for amputee patients and prosthetic clinic customers. The acquisition was not reportable under the Hart-Scott-Rodino Act. The Commission’s order requires Otto Bock to divest the Freedom Innovations assets to an FTC-approved buyer.
Featured News
Teva Reaches Settlement With US States Over Generic Drug Price-Fixing
Nov 17, 2026 by
CPI
US Justice Department to Review DoorDash’s $17 Billion Instacart Deal
Nov 17, 2026 by
CPI
AstraZeneca Wins Dismissal of Soliris Antitrust Lawsuit
Nov 17, 2026 by
CPI
Sony Wins $2.64 Billion UK PlayStation Antitrust Case Over Digital Game Pricing
Nov 17, 2026 by
CPI
Spain’s Competition Regulator Plans to Turn Barcelona Headquarters Into Digital Hub
Nov 17, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data Portability
Nov 12, 2026 by
CPI
Mandating Access to a Dominant Platform’s Inferred Data: A Two Scenario Diagnosis
Nov 12, 2026 by
Sean Ennis
Data Portability Between Individual Control and Data Sharing at Scale
Nov 12, 2026 by
Jasper van den Boom & Inge Graef
Information Also Wants to Be Expensive: Data Portability and the Open-Systems Creed
Nov 12, 2026 by
Justin (Gus) Hurwitz
Data Portability’s Cybersecurity Paradox: When Protecting Consumer Data Restricts Competition
Nov 12, 2026 by
Sasha Hondagneu-Messner